IP Library Granted Patent US 7,476,539
Granted Patent B2
US 7,476,539 · App. 11/267,182 · Granted Jan 13, 2009

DNA containing variant FRT sequences

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,476,539
App. No.
11/267,182
Granted
Jan 13, 2009
Kind
B2
Abstract

To provide DNA comprising mutant FRT sequence which causes recombination reaction between two mutant FRT sequences having an identical sequence to each other but does not cause recombination reaction with a wild-type FRT sequence, in the presence of FLP recombinase; and a method for performing high-efficiency, gene insertion or gene replacement. A DNA comprising a mutant FRT sequence (any one of SEQ ID NOs: 2 to 5); a DNA comprising a mutant FRT sequence possessing (A) causing no specific DNA recombination reaction with wild type FRT, even if FLP recombinase is present, and (B) causing specific DNA recombination reaction with another mutant FRT sequence having an identical sequence thereto in the presence of recombinase FLP, wherein the mutant FRT sequence has substitutions of at least one nucleotide in a region other than the spacer region in the sequence and a cell which is transformed with the DNA.

Claims (10)

1. An isolated DNA comprising a mutant FRT sequence comprising the sequence set forth as SEQ ID NO: 2, 3, 4 or 5 with the exception that at least one nucleotide is substituted in the SEQ ID NO: 2, 3, 4 or 5 sequence at a position other than the 8-bp spacer region spanning nucleotide positions 14-21, wherein said mutant FRT sequence possesses the following properties (A) and (B):

(A) causing no specific DNA recombination reaction with wild type FRT, even if FLP recombinase is present, and

(B) causing specific DNA recombination reaction with another mutant FRT sequence having an identical sequence thereto in the presence of recombinase FLP.

2. The DNA according to claim 1 , wherein said mutant FRT sequence possesses the property of causing no specific DNA recombination reaction with a mutant FRT sequence having a different sequence in the 8-bp spacer region in the presence of recombinase FLP.

3. An isolated DNA comprising at least one wild type FRT sequence and at least one mutant FRT sequence defined in claim 1 .

4. An isolated DNA comprising at least two mutant FRT seqences defined in claim 1 , wherein the mutant FRT sequences are different relative to one another in the 8-bp spacer region.

5. The DNA according to claim 3 , having a desired nucleotide sequence between the wild type FRT sequence and the mutant FRT sequence.

6. An isolated cell which is transformed with the DNA of claim 3 in vitro.

7. A non-human cell which is transformed with the DNA of claim 3 .

8. The DNA according to claim 4 , further comprising a desired nucleotide sequence between the two mutant FRT sequences.

Assignments (1)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →